Note 10 - Commitments and Contingencies (Details Textual)						1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 20, 2021 USD ($) shares	May 29, 2020 USD ($)	Mar. 31, 2020 USD ($) shares	Mar. 20, 2020 USD ($) shares	Nov. 01, 2019 USD ($)	Jan. 31, 2020 USD ($)	May 31, 2016 USD ($)	Mar. 31, 2021 USD ($) shares	Mar. 31, 2020 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jan. 31, 2021 USD ($)	May 01, 2020 USD ($)	Feb. 14, 2020 USD ($)	Feb. 28, 2015 USD ($)
Contractual Obligation, Total								$ 35,117,000		$ 35,117,000
Tris Pharma, Inc. [Member] | Karbinal Agreement [Member]
Supply and Distribution Commitment, Period (Year)					20 years
Supply and Distribution Commitment, Total Royalty, Percentage of Net Sales					23.50%
Supply and Distribution Commitment, Third Party, Royalty, Percentage of Net Sales					8.50%
Supply and Distribution Commitment, Royalty, Percentage of Net Sales													15.00%	15.00%
Supply and Distribution Agreement, Maximum Yearly Make-whole Payment					$ 2,100,000
Supply and Distribution Agreement, Minimum Sales Per Year					70,000
Supply and Distribution Agreement, Make-whole Payment Per Unit for Sales Under Minimum					$ 30
Supply and Distribution Agreement, Maximum Milestone Obligations					3,000,000
Supply and Distribution Agreement, First Milestone, Minimum Net Revenues					40,000,000
Innovus Pharmaceuticals [Member]
Stock Issued During Period, Shares, Contingent Value Rights (in shares) | shares	103,000		120,000	103,000				120,000
Stock Issued During Period, Value, Contingent Value Rights	$ 1,000,000		$ 2,000,000	$ 1				$ 1,000,000
Business Combination, Contingent Value Rights, First Revenue Milestone	30,000,000		24,000,000	0.40				24,000,000	$ 24,000,000	24,000,000	$ 24,000,000
Gain (Loss) from Change in Fair Value of CVR	$ (100,000)		$ 300,000	$ 30				400,000	$ (200,000)	1,000,000	$ 200,000	$ 300,000
Business Combination, Contingent Consideration, Liability, Total																	$ 200,000
Novalere [Member] | Innovus Pharmaceuticals [Member]
Business Acquisition, Contingent Consideration, Number of Payments																		5
Business Acquisition, Contingent Consideration, Payment Upon Each Sales Milestone																		$ 500,000
Business Combination, Contingent Consideration, Liability, Total								200,000		200,000
Prescription Database [Member]
Unrecorded Unconditional Purchase Obligation, Total							$ 1,600,000
Unrecorded Unconditional Purchase Obligation, Term (Year)							3 years
Contractual Obligation, Total								1,145,000		1,145,000
Prescription Database [Member] | The Pediatric Portfolio [Member]
Unrecorded Unconditional Purchase Obligation, Total						$ 600,000
First Pediatric Portfolio Fixed Obligation [Member]
Contractual Obligation, Monthly Payment															$ 86,840
Contractual Obligation, Balloon Payment															$ 15,000,000
Repayments of Fixed Obligation		$ 15,000,000
Second Pediatric Portfolio Fixed Obligation [Member]
Contractual Obligation, Monthly Payment					$ 100,000
Payments for Fixed Obligations to Investor						$ 210,767
Inventories [Member]
Contractual Obligation, Total								1,472,000		1,472,000
Inventories [Member] | Hikma Pharmaceuticals USA, Inc. [Member]
Unrecorded Unconditional Purchase Obligation, Total																$ 1,000,000
Product Milestone Payments [Member]
Contractual Obligation, Total								$ 3,000,000		$ 3,000,000